These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15536331)

  • 1. Prognostic significance of dysadherin expression in tongue cancer: immunohistochemical analysis of 91 cases.
    Nakanishi Y; Akimoto S; Sato Y; Kanai Y; Sakamoto M; Hirohashi S
    Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):323-8. PubMed ID: 15536331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.
    Nishizawa A; Nakanishi Y; Yoshimura K; Sasajima Y; Yamazaki N; Yamamoto A; Hanada K; Kanai Y; Hirohashi S
    Cancer; 2005 Apr; 103(8):1693-700. PubMed ID: 15751018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the dysadherin and E-cadherin expression in primary lung cancer and metastatic sites.
    Mitselou A; Batistatou A; Nakanishi Y; Hirohashi S; Vougiouklakis T; Charalabopoulos K
    Histol Histopathol; 2010 Oct; 25(10):1257-67. PubMed ID: 20712010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of dysadherin expression in advanced colorectal carcinoma.
    Aoki S; Shimamura T; Shibata T; Nakanishi Y; Moriya Y; Sato Y; Kitajima M; Sakamoto M; Hirohashi S
    Br J Cancer; 2003 Mar; 88(5):726-32. PubMed ID: 12618882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma.
    Shimada Y; Hashimoto Y; Kan T; Kawamura J; Okumura T; Soma T; Kondo K; Teratani N; Watanabe G; Ino Y; Sakamoto M; Hirohashi S; Imamura M
    Oncology; 2004; 67(1):73-80. PubMed ID: 15459499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to e-cadherin expression.
    Shimamura T; Sakamoto M; Ino Y; Sato Y; Shimada K; Kosuge T; Sekihara H; Hirohashi S
    J Clin Oncol; 2003 Feb; 21(4):659-67. PubMed ID: 12586803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of dysadherin expression in patients with non-small cell lung cancer.
    Tamura M; Ohta Y; Tsunezuka Y; Matsumoto I; Kawakami K; Oda M; Watanabe G
    J Thorac Cardiovasc Surg; 2005 Sep; 130(3):740-5. PubMed ID: 16153922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma: special reference to its inverse relationship with E-cadherin expression.
    Izumi T; Oda Y; Hasegawa T; Nakanishi Y; Kawai A; Sonobe H; Takahira T; Kobayashi C; Yamamoto H; Tamiya S; Hirohashi S; Iwamoto Y; Tsuneyoshi M
    Am J Surg Pathol; 2007 Jan; 31(1):85-94. PubMed ID: 17197923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysadherin expression in head and neck squamous cell carcinoma: association with lymphangiogenesis and prognostic significance.
    Kyzas PA; Stefanou D; Batistatou A; Agnantis NJ; Nakanishi Y; Hirohashi S; Charalabopoulos K
    Am J Surg Pathol; 2006 Feb; 30(2):185-93. PubMed ID: 16434892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma.
    Batistatou A; Charalabopoulos AK; Scopa CD; Nakanishi Y; Kappas A; Hirohashi S; Agnantis NJ; Charalabopoulos K
    Virchows Arch; 2006 Jun; 448(6):763-7. PubMed ID: 16570180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of dysadherin and cytokeratin as prognostic indicators of disease-free survival in patients with stage I NSCLC.
    Ono K; Uramoto H; Hanagiri T
    Anticancer Res; 2010 Sep; 30(9):3273-8. PubMed ID: 20944097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin.
    Batistatou A; Peschos D; Tsanou H; Charalabopoulos A; Nakanishi Y; Hirohashi S; Agnantis NJ; Charalabopoulos K
    Br J Cancer; 2007 May; 96(9):1404-8. PubMed ID: 17437014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of dysadherin expression in gastric cancer patients.
    Shimada Y; Yamasaki S; Hashimoto Y; Ito T; Kawamura J; Soma T; Ino Y; Nakanishi Y; Sakamoto M; Hirohashi S; Imamura M
    Clin Cancer Res; 2004 Apr; 10(8):2818-23. PubMed ID: 15102690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of dysadherin and E-cadherin expression in differentiated-type gastric carcinoma with submucosal invasion.
    Maehata Y; Hirahashi M; Aishima S; Kishimoto J; Hirohashi S; Yao T; Takashima H; Tsuneyoshi M; Oda Y
    Hum Pathol; 2011 Apr; 42(4):558-67. PubMed ID: 21239043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of dysadherin and E-cadherin expression in patients with head and neck cancer treated by radiation therapy.
    Muramatsu H; Akimoto T; Maebayashi K; Kita M; Mitsuhashi N
    Anticancer Res; 2008; 28(6B):3859-64. PubMed ID: 19192641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysadherin expression in gastrointestinal stromal tumors (GISTs).
    Liang JF; Zheng HX; Xiao H; Li N; Cheng CX; Wang HK
    Pathol Res Pract; 2009; 205(7):445-50. PubMed ID: 19217217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of dysadherin expression in cervical squamous cell carcinoma.
    Wu D; Qiao Y; Kristensen GB; Li S; Troen G; Holm R; Nesland JM; Suo Z
    Pathol Oncol Res; 2004; 10(4):212-8. PubMed ID: 15619642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysadherin: a new player in cancer progression.
    Nam JS; Hirohashi S; Wakefield LM
    Cancer Lett; 2007 Oct; 255(2):161-9. PubMed ID: 17442482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of dysadherin and E-cadherin in the development of testicular tumours.
    Batistatou A; Scopa CD; Ravazoula P; Nakanishi Y; Peschos D; Agnantis NJ; Hirohashi S; Charalabopoulos KA
    Br J Cancer; 2005 Dec; 93(12):1382-7. PubMed ID: 16333245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilitates cell-cell adhesion.
    Tsuiji H; Takasaki S; Sakamoto M; Irimura T; Hirohashi S
    Glycobiology; 2003 Jul; 13(7):521-7. PubMed ID: 12672699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.